Modality
Peptide
MOA
KRASG12Di
Target
AuroraA
Pathway
Complement
T2D
Development Pipeline
Preclinical
~Aug 2017
→ ~Nov 2018
Phase 1
~Feb 2019
→ ~May 2020
Phase 2
Aug 2020
→ Aug 2025
Phase 2Current
NCT08185015
199 pts·T2D
2020-08→2025-08·Active
199 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2025-08-257mo agoPh2 Data· T2D
Trial Timeline
Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q4
P2
Active
Catalysts
Ph2 Data
2025-08-25 · 7mo ago
T2D
Active|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT08185015 | Phase 2 | T2D | Active | 199 | Mayo |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Doxarasimod | Merck & Co | NDA/BLA | FGFR | |
| Zanusertib | AbbVie | Approved | PCSK9 | |
| Pexarelsin | AstraZeneca | Phase 1 | DLL3 | |
| Motarapivir | GSK | Preclinical | AuroraA | |
| Ivotuximab | GSK | NDA/BLA | GIP-R | |
| BAY-8733 | Bayer | Preclinical | AuroraA | |
| BNT-8090 | BioNTech | Phase 2 | AuroraA | |
| ARG-6988 | Argenx | Preclinical | AuroraA | |
| Terarasimod | Krystal Biotech | Phase 1/2 | PI3Kα | |
| Semamavacamten | Ideaya Bio | Phase 1/2 | AuroraA |